Indication: Prostate Cancer
An Extended/Phase 2, Multi-Center, Randomized, Open-Label Study to Evaluate the Safety and Tolerability of Proxalutamide (GT0918) in Subjects with Metastatic Castrate Resistant Prostate Cancer (mCRPC) who Failed Either Abiraterone or Enzalutamide
Metastatic Castrate Resistant
Sub-indication: Progressive disease despite hormonal treatment with abiraterone or enzalutamide, but not both. One line of chemotherapy is eligible
Line of Therapy: 2nd Line
Principal Investigator: Chandler Park, M.D.Norton Cancer Institute
Sponsor: Suzhou Kintor Pharmaceuticals, Inc.
Email for more information: GU-NCIResearch@nortonhealthcare.org